New pooled analysis shows cangrelor demonstrates reduction in angiographic complications compared to oral clopidogrel

The Medicines Company (NASDAQ: MDCO) reported presentation and publication of a pooled analysis of three Phase III clinical trials of an investigational intravenous (IV) antiplatelet, cangrelor. The trials compared IV cangrelor to either oral clopidogrel or placebo for prevention of thrombotic (clotting) complications during and after percutaneous coronary intervention (PCI). The findings of the pooled CHAMPION program confirm the results of the CHAMPION PHOENIX trial presented and published in April 2013...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/ld34YBdeevE/265700.php

rehab sport sport medical